GlassScriptPhysician profile
Daniel George Gates
NPI 1922066596
$1,515.18
in general payments reported to CMS, 2019-2025
20 companies · $927 in 2025
The $927 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.20 · 2024: $571 · 2025: $927.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,498.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,497.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $256.89 | 2024-2025 | |
| Baxter Healthcare | $235.45 | 2025 | Hillrom - Carnation Ambulatory Monitor, Hillrom - Cardiac Ambulatory Monitor |
| Medtronic, INC. | $148.63 | 2025 | Aurora Ev-Icd Mri Surescan |
| E.R. Squibb & Sons, L.L.C. | $118.82 | 2024-2025 | Eliquis, Camzyos |
| Amgen INC. | $113.12 | 2024-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $103.41 | 2024 | Bodyguardian, Lux-Dx Insertable Cardiac Monitor |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.57 | 2024-2025 | Jardiance |
| Pfizer INC. | $79.06 | 2024-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $77.23 | 2024 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $46.87 | 2024-2025 | Farxiga, Wainua |
| Merck Sharp & Dohme LLC | $44.89 | 2024 | Verquvo |
| Alnylam Pharmaceuticals INC. | $35.86 | 2025 | Amvuttra |
| Ionis Pharmaceuticals, INC. | $28.09 | 2025 | Tryngolza |
| Bayer Healthcare Pharmaceuticals INC. | $24.24 | 2025 | |
| Recor Medical INC | $24.16 | 2025 | Paradise Ultrasound Renal Denervation System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $22.69 | 2024 | Nexletol |
| Biotronik INC. | $21.80 | 2025 | Renamic Neo |
| Abiomed | $19.36 | 2025 | |
| Janssen Pharmaceuticals, INC | $17.20 | 2019 | |
| Scpharmaceuticals INC. | $14.84 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Gates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.